Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Microsoft Excel

Long-term Activity Ratios (Summary)

Abbott Laboratories, long-term (investment) activity ratios (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net fixed asset turnover 3.95 4.18 4.26 4.47 4.76 5.18 5.17 5.00 4.81 4.79 4.56 4.23 3.83 3.74 3.77 4.06 3.97
Total asset turnover 0.55 0.55 0.55 0.56 0.59 0.62 0.61 0.60 0.57 0.57 0.55 0.51 0.48 0.47 0.46 0.48 0.47
Equity turnover 1.04 1.07 1.08 1.12 1.19 1.26 1.25 1.26 1.20 1.23 1.19 1.11 1.06 1.03 1.03 1.06 1.03

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Abbott Laboratories net fixed asset turnover ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Abbott Laboratories total asset turnover ratio improved from Q2 2023 to Q3 2023 but then deteriorated significantly from Q3 2023 to Q4 2023.
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Abbott Laboratories equity turnover ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.

Net Fixed Asset Turnover

Abbott Laboratories, net fixed asset turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Net sales 10,241 10,143 9,978 9,747 10,091 10,410 11,257 11,895 11,468 10,928 10,223 10,456 10,701 8,853 7,328 7,726 8,314 8,076 7,979 7,535
Net property and equipment 10,154 9,552 9,449 9,282 9,162 8,689 8,818 8,908 8,959 8,831 8,816 8,832 9,029 8,620 8,343 7,907 8,038 7,825 7,825 7,626
Long-term Activity Ratio
Net fixed asset turnover1 3.95 4.18 4.26 4.47 4.76 5.18 5.17 5.00 4.81 4.79 4.56 4.23 3.83 3.74 3.77 4.06 3.97
Benchmarks
Net Fixed Asset Turnover, Competitors2
Cigna Group 52.53 48.12 47.67 47.44 47.53 47.84 48.61 47.95 46.73 41.42 40.56 39.29 37.85 37.05 36.02 35.37 34.45
CVS Health Corp. 27.05 26.62 26.00 25.63 24.98 24.90 24.05 23.26 22.56 22.24 21.90 21.42 21.25 21.48 21.52 21.49 21.24
Danaher Corp. 5.25 6.87 7.27 7.61 7.96 8.40 8.12 7.94 7.77 7.71 7.84 7.59 6.83 6.68 6.35 6.03 7.78
Elevance Health Inc. 39.05 39.41 36.19 36.14 36.07 36.22 36.17 35.81 34.94 34.54 34.17 34.94 34.69 34.61 32.74 32.30 32.92
Humana Inc. 34.75 30.35 29.59 29.40 28.71 28.37 28.64 27.05 26.97 27.83 29.47 31.04 32.05 32.90 33.07 33.20 32.93
Intuitive Surgical Inc. 2.01 2.23 2.35 2.49 2.62 2.73 2.83 3.00 3.04 3.16 3.13 2.86 2.76 2.85 3.00 3.36 3.52
Medtronic PLC 5.61 5.66 5.82 5.88 5.85 6.05 6.13 6.12 5.77 5.56 5.64 5.72 5.99 6.52 6.50 6.51 6.54 6.65 6.70 6.62
UnitedHealth Group Inc. 32.10 32.18 31.60 31.35 31.81 33.07 32.33 32.16 31.81 31.77 30.94 30.76 29.64 30.80 30.30 29.91 27.60

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
Net fixed asset turnover = (Net salesQ4 2023 + Net salesQ3 2023 + Net salesQ2 2023 + Net salesQ1 2023) ÷ Net property and equipment
= (10,241 + 10,143 + 9,978 + 9,747) ÷ 10,154 = 3.95

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Abbott Laboratories net fixed asset turnover ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.

Total Asset Turnover

Abbott Laboratories, total asset turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Net sales 10,241 10,143 9,978 9,747 10,091 10,410 11,257 11,895 11,468 10,928 10,223 10,456 10,701 8,853 7,328 7,726 8,314 8,076 7,979 7,535
Total assets 73,214 72,090 73,354 73,794 74,438 72,801 74,202 74,007 75,196 73,795 73,269 72,785 72,548 69,043 68,776 66,777 67,887 68,539 68,427 67,610
Long-term Activity Ratio
Total asset turnover1 0.55 0.55 0.55 0.56 0.59 0.62 0.61 0.60 0.57 0.57 0.55 0.51 0.48 0.47 0.46 0.48 0.47
Benchmarks
Total Asset Turnover, Competitors2
Cigna Group 1.27 1.26 1.23 1.23 1.25 1.24 1.17 1.15 1.11 1.09 1.07 1.06 1.02 0.97 0.96 0.99 0.98
CVS Health Corp. 1.43 1.38 1.35 1.38 1.41 1.36 1.33 1.28 1.25 1.21 1.20 1.18 1.16 1.14 1.12 1.13 1.15
Danaher Corp. 0.28 0.34 0.36 0.36 0.37 0.39 0.38 0.36 0.35 0.34 0.34 0.33 0.29 0.28 0.27 0.26 0.29
Elevance Health Inc. 1.56 1.52 1.51 1.46 1.51 1.48 1.47 1.42 1.41 1.35 1.33 1.29 1.39 1.34 1.28 1.31 1.33
Humana Inc. 2.24 1.81 1.73 1.74 2.15 1.80 1.91 1.86 1.87 1.78 2.08 2.08 2.17 1.90 1.82 1.94 2.21
Intuitive Surgical Inc. 0.46 0.47 0.48 0.49 0.48 0.46 0.44 0.43 0.42 0.42 0.42 0.39 0.39 0.41 0.43 0.47 0.46
Medtronic PLC 0.34 0.33 0.33 0.35 0.35 0.35 0.35 0.34 0.32 0.29 0.29 0.30 0.32 0.33 0.34 0.34 0.34 0.34 0.34 0.33
UnitedHealth Group Inc. 1.34 1.26 1.23 1.18 1.31 1.29 1.32 1.33 1.34 1.30 1.29 1.27 1.30 1.31 1.28 1.29 1.38

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
Total asset turnover = (Net salesQ4 2023 + Net salesQ3 2023 + Net salesQ2 2023 + Net salesQ1 2023) ÷ Total assets
= (10,241 + 10,143 + 9,978 + 9,747) ÷ 73,214 = 0.55

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Abbott Laboratories total asset turnover ratio improved from Q2 2023 to Q3 2023 but then deteriorated significantly from Q3 2023 to Q4 2023.

Equity Turnover

Abbott Laboratories, equity turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Net sales 10,241 10,143 9,978 9,747 10,091 10,410 11,257 11,895 11,468 10,928 10,223 10,456 10,701 8,853 7,328 7,726 8,314 8,076 7,979 7,535
Total Abbott shareholders’ investment 38,603 37,481 37,174 37,010 36,686 35,675 36,490 35,399 35,802 34,422 33,800 33,562 32,784 31,386 30,578 30,218 31,088 31,817 31,686 30,925
Long-term Activity Ratio
Equity turnover1 1.04 1.07 1.08 1.12 1.19 1.26 1.25 1.26 1.20 1.23 1.19 1.11 1.06 1.03 1.03 1.06 1.03
Benchmarks
Equity Turnover, Competitors2
Cigna Group 4.20 4.13 4.07 4.09 4.00 3.98 3.88 3.81 3.66 3.56 3.40 3.36 3.16 3.24 3.24 3.39 3.36
CVS Health Corp. 4.66 4.66 4.65 4.62 4.53 4.45 4.08 4.05 3.87 3.82 3.79 3.81 3.86 3.86 3.87 4.01 4.00
Danaher Corp. 0.45 0.56 0.59 0.60 0.63 0.67 0.66 0.65 0.65 0.65 0.62 0.61 0.56 0.54 0.52 0.58 0.59
Elevance Health Inc. 4.33 4.36 4.31 4.27 4.29 4.22 4.13 3.97 3.80 3.71 3.65 3.65 3.64 3.43 3.26 3.41 3.25
Humana Inc. 6.48 5.98 5.82 5.74 6.04 5.62 5.77 5.63 5.15 4.96 5.34 5.48 5.54 4.65 4.86 5.44 5.35
Intuitive Surgical Inc. 0.54 0.55 0.56 0.57 0.56 0.53 0.50 0.49 0.48 0.48 0.48 0.45 0.45 0.47 0.50 0.54 0.54
Medtronic PLC 0.61 0.60 0.59 0.59 0.60 0.60 0.61 0.61 0.59 0.55 0.56 0.56 0.57 0.60 0.61 0.61 0.61 0.61 0.61 0.60
UnitedHealth Group Inc. 4.14 4.22 4.19 4.10 4.14 4.19 4.18 4.06 3.98 3.95 3.92 3.94 3.90 3.85 3.87 4.29 4.17

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
Equity turnover = (Net salesQ4 2023 + Net salesQ3 2023 + Net salesQ2 2023 + Net salesQ1 2023) ÷ Total Abbott shareholders’ investment
= (10,241 + 10,143 + 9,978 + 9,747) ÷ 38,603 = 1.04

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Abbott Laboratories equity turnover ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.